Massmutual Trust Co. FSB ADV Buys 48,100 Shares of Cryo-Cell International, Inc. (OTCMKTS:CCEL)

Massmutual Trust Co. FSB ADV raised its stake in Cryo-Cell International, Inc. (OTCMKTS:CCELGet Rating) by 63.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 124,135 shares of the company’s stock after purchasing an additional 48,100 shares during the period. Massmutual Trust Co. FSB ADV owned 1.47% of Cryo-Cell International worth $732,000 as of its most recent SEC filing.

Separately, SFI Advisors LLC bought a new stake in shares of Cryo-Cell International during the fourth quarter worth about $1,567,000. Institutional investors own 9.01% of the company’s stock.

Cryo-Cell International Stock Up 7.1 %

OTCMKTS CCEL opened at $7.50 on Friday. The company’s 50 day moving average is $6.10 and its 200-day moving average is $6.50. Cryo-Cell International, Inc. has a 12-month low of $5.00 and a 12-month high of $14.00. The firm has a market cap of $62.93 million, a P/E ratio of 39.48 and a beta of 0.44.

Cryo-Cell International (OTCMKTS:CCELGet Rating) last posted its quarterly earnings results on Monday, July 11th. The company reported $0.07 earnings per share (EPS) for the quarter. Cryo-Cell International had a net margin of 5.68% and a return on equity of 38.25%. The company had revenue of $7.63 million for the quarter.

Cryo-Cell International Announces Dividend

The company also recently announced a dividend, which was paid on Friday, September 9th. Investors of record on Friday, September 2nd were issued a dividend of $0.90 per share. The ex-dividend date of this dividend was Thursday, September 1st.

Analysts Set New Price Targets

Separately, Maxim Group assumed coverage on shares of Cryo-Cell International in a report on Monday, August 29th. They set a “buy” rating and a $12.00 price target on the stock.

Cryo-Cell International Company Profile

(Get Rating)

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases.

Featured Stories

Want to see what other hedge funds are holding CCEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cryo-Cell International, Inc. (OTCMKTS:CCELGet Rating).

Institutional Ownership by Quarter for Cryo-Cell International (OTCMKTS:CCEL)

Receive News & Ratings for Cryo-Cell International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryo-Cell International and related companies with MarketBeat.com's FREE daily email newsletter.